Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Head and
How well does radiation therapy work with durvalumab or cetuximab in treating patients
with head and neck cancer that has spread to a local and/or regional area of the body
and who cannot take cisplatin?
Basic Study Information
Purpose:Location: University of Rochester Medical Center
This randomized phase II/III trial studies how well radiation therapy works with durvalumab
or cetuximab in treating patients with head and neck cancer that has spread to a local
and/or regional area of the body who cannot take cisplatin. Radiation therapy uses
high energy x-rays to kill tumor cells and shrink tumors. Immunotherapy with monoclonal
antibodies, such as durvalumab or cetuximab, may help the body's immune system attack
the cancer, and may interfere with the ability of tumor cells to grow and spread.
It is not known if radiation therapy with durvalumab will work better than the usual
therapy of radiation therapy with cetuximab in treating patients with head and neck
Study Reference #: RHAN18031
Lead Researcher (Principal Investigator)
Study Contact InformationStudy Coordinator: Therese Smudzin
Phone: (585) 275-7848
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search